NBTX
Nanobiotix S.A.·Healthcare
30.34
0.817%(−0.25)
Market ClosedLast Updated: — ET
52W L: $3.1252W H: $41.89
NBTX NEWS
globenewswire.com
4d ago
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
defenseworld.net
Apr 4
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $34.07, but opened at $31.03. Nanobiotix shares last traded at $30.8590, with a volume of 14,146 shares. Analyst Upgrades and Downgrades A number of research firms have issued reports on
defenseworld.net
Apr 3
Nanobiotix H2 Earnings Call Highlights
Nanobiotix (NASDAQ: NBTX) executives said the company made "a very rich" set of operational and financial moves in 2025, highlighting progress in its Johnson and Johnson collaboration around NBTXR3/JNJ-1900, a continued pivot toward its Curadigm nanoprimer platform, and an extended cash runway into early 2028. Johnson and Johnson collaboration: head and neck Phase III and lung
seekingalpha.com
Apr 1
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 31
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Clinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312 Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Advanced the Curadigm Nanoprimer platform with four new patent applications filed, new in vivo data presentations, external collaboration momentum building, and the launch of Chemistry, Manufacturing, and Controls (CMC) activities to support both internal pipeline and external collaborations Cash runway extended into early 2028 with €52.8 million in cash and cash equivalents as of December 31, 2025 Clinical data readouts expected in 2026 from Phase 1 and 2 studies in NSCLC (re-irradiation), pancreatic cancer, melanoma and esophageal cancer Conference call and webcast scheduled for April 1, 2026, at 8:00 A.M. EDT / 2:00 P.M.
globenewswire.com
Mar 26
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
